Merck Faces European Keytruda SC Halt While Building $3B Virginia Plant
Merck & Co., Inc. (NYSE:MRK) is navigating major operational and legal developments after a Dutch court ordered a halt to the manufacture and sale of Keytruda SC across eight European countries due to a patent infringement dispute with Halozyme. Merck disputes the ruling and is reviewing its options. Meanwhile, the pharmaceutical company broke ground on a $3B facility in Virginia as part of a broader plan to invest more than $70B in domestic manufacturing and research capacity.
The conflicting news comes as Wall Street analysts adjust their outlooks on the company. JPMorgan bumped its price target to $165 while maintaining a Buy rating, pointing to a refreshed near-term outlook despite long-term growth reassessments. Cantor Fitzgerald raised its target to $145 with a Neutral rating, warning that revenue and earnings per share estimates for 2027 might face cuts. Additionally, lawmakers included the company in a broader research-site data protection inquiry, though no illegal activity was found.
Investors will be watching how Merck responds to the European legal restriction and how upcoming clinical trial data from the ESMO cancer conference might influence share performance. Shares of Merck & Co., Inc. were up 2.26% today, trading at $145.60.
Key points
- A Dutch court ordered a halt to Keytruda SC production and sales in eight European countries over a Halozyme patent dispute.
- Merck disputes the European court ruling and is currently reviewing its legal options.
- Construction began on a $3B drug manufacturing plant in Virginia as part of a $70B-plus U.S. investment effort.
- JPMorgan raised its price target for Merck to $165, while Cantor Fitzgerald increased its target to $145.
- A U.S. congressional inquiry into research site data protection named Merck, finding no evidence of unlawful conduct.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did a European court order a halt on Merck's Keytruda SC sales?
A Dutch court ruled that Merck infringed on Halozyme's MDASE patent, ordering a halt to the manufacture and sales of Keytruda SC across eight European nations. Merck disputes the verdict and is reviewing its legal options.
Where is Merck building its new manufacturing facility?
Merck has begun constructing a $3B drug manufacturing plant in Virginia. The project is part of a broader effort to invest over $70B in boosting domestic manufacturing and research infrastructure in the U.S.
What are analysts saying about Merck's stock?
JPMorgan raised its price target to $165 with a Buy rating, citing an updated near-term outlook. Cantor Fitzgerald increased its target to $145 with a Neutral rating, noting potential cuts to 2027 revenue and earnings expectations.